Abeona Therapeutics Appoints Experienced Biotech CFO Keith Goldan to Board, Chairs Audit Committee

summarizeSummary

Abeona Therapeutics has appointed Keith A. Goldan, an experienced biotech CFO, as an independent director and Chair of its Audit Committee, bolstering financial leadership during its commercialization phase.

check_boxKey Events · Executive and Board Changes · ABEO

• New Independent Director Appointed

  Keith A. Goldan, an experienced financial leader in commercial-stage biotechnology and specialty pharmaceuticals, has been appointed as a Class 1 independent director to the Board, effective April 1, 2026.

• Chairs Audit Committee

  Mr. Goldan will serve as the Chair of the Audit Committee, enhancing the company's financial oversight and governance.

• Relevant Industry Experience

  Mr. Goldan brings over two decades of financial leadership, including CFO roles at Syndax Pharmaceuticals and Optinose, with experience in capital markets, corporate development, and operational scaling for commercial-stage biotech companies.

• Compensation Details

  Mr. Goldan will receive an annual Board fee of $50,000 in cash and a one-time sign-on equity grant of $150,000 in restricted stock awards with a one-year vesting period.

auto_awesomeAnalysis · ABEO · Life Sciences

The appointment of Keith A. Goldan, an accomplished financial leader with extensive experience in commercial-stage biotechnology, strengthens Abeona's Board of Directors and its Audit Committee. His background in capital markets, corporate development, and operational scaling is particularly relevant as Abeona continues to commercialize ZEVASKYN and pursue strategic growth initiatives. This move enhances corporate governance and financial oversight during a critical growth phase for the company, following recent positive news regarding ZEVASKYN's commercial activation.